An Observational Study to Develop Algorithms for Identifying Opioid Abuse and Addiction Based on Admin Claims Data
2 other identifiers
observational
1,667
0 countries
N/A
Brief Summary
The purpose of this study is to develop and validate a classification model based entirely on medical claims data that can be used to identify patients experiencing prescription opioid abuse/addiction among patients receiving extended-release (ER) and/or long-acting (LA) opioids
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2015
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 20, 2015
CompletedFirst Submitted
Initial submission to the registry
January 18, 2016
CompletedFirst Posted
Study publicly available on registry
January 28, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 17, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 17, 2017
CompletedApril 15, 2020
April 1, 2020
2 years
January 18, 2016
April 14, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Opioid abuse/addiction
This will be assessed from three data sources: a diagnostic algorithm that uses coded terms in claims data, Natural Language Processing assessment of text in electronic medical records, and medical chart review by clinicians trained in chart review
Retrospective review of data from 2006 to 2015, up to 9 years
Study Arms (1)
Extended Release and/or Long-Acting Opioids
Interventions
Eligibility Criteria
Patients with at least two years continuous enrollment in Group Health integrated group practice (IGP) receiving ER/LA opioid analgesics
You may qualify if:
- Age ≥ 18 years
- Receipt of at least a 60 day's supply of ER/LA opioid analgesics within a 90-day period (including transdermal or oral opioids but excluding buprenorpine)
- Minimum of at least two years continuous enrollment in Group Health integrated group practice (IGP)
You may not qualify if:
- Residence in a nursing home at any time during the study period
- Enrollment in a hospice care program at any time during the study period
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Member Companies of the Opioid PMR Consortiumlead
- World Health Information Science Consultants, LLCcollaborator
- Kaiser Permanentecollaborator
Related Publications (1)
Carrell DS, Albertson-Junkans L, Ramaprasan A, Scull G, Mackwood M, Johnson E, Cronkite DJ, Baer A, Hansen K, Green CA, Hazlehurst BL, Janoff SL, Coplan PM, DeVeaugh-Geiss A, Grijalva CG, Liang C, Enger CL, Lange J, Shortreed SM, Von Korff M. Measuring problem prescription opioid use among patients receiving long-term opioid analgesic treatment: development and evaluation of an algorithm for use in EHR and claims data. J Drug Assess. 2020 Apr 28;9(1):97-105. doi: 10.1080/21556660.2020.1750419. eCollection 2020.
PMID: 32489718DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Paul Coplan, MS, ScD, MBA
Purdue Pharma LP
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 18, 2016
First Posted
January 28, 2016
Study Start
May 20, 2015
Primary Completion
May 17, 2017
Study Completion
May 17, 2017
Last Updated
April 15, 2020
Record last verified: 2020-04